What to Do If You’re Diagnosed with Gestational Diabetes

Managing gestational diabetes requires a proactive, multidisciplinary approach focused on maintaining optimal glycemic control to safeguard both maternal and fetal health. Gestational diabetes mellitus (GDM) is defined as glucose intolerance with onset or first recognition during pregnancy—typically diagnosed between 24 and 28 weeks’ gestation via oral glucose tolerance testing. Unlike preexisting type 1 or type 2 diabetes, GDM arises from progressive insulin resistance driven by placental hormones, particularly in the second and third trimesters.

Initial management centers on medical nutrition therapy and structured physical activity. A registered dietitian should tailor an individualized meal plan emphasizing consistent carbohydrate distribution, high-fiber whole foods, lean protein, and healthy fats—while avoiding concentrated sugars and refined carbohydrates. Moderate-intensity aerobic exercise, such as brisk walking or swimming for at least 30 minutes most days of the week, enhances insulin sensitivity and supports postprandial glucose stabilization.

Self-monitoring of blood glucose (SMBG) is essential: patients are typically advised to check fasting and one-hour postprandial values daily. Target goals generally include fasting glucose ≤95 mg/dL (5.3 mmol/L) and one-hour postprandial glucose ≤140 mg/dL (7.8 mmol/L), though specific targets may vary based on clinical guidelines and individual risk factors.

When lifestyle interventions fail to achieve glycemic targets within 1–2 weeks—or if initial glucose values are markedly elevated—pharmacologic therapy is indicated. Insulin remains the first-line pharmacologic agent due to its lack of placental transfer and well-established safety profile. Common regimens include basal insulin (e.g., neutral protamine Hagedorn [NPH] or insulin glargine) alone or in combination with rapid-acting insulin before meals. In select cases and where approved by local regulatory authorities, oral agents such as metformin may be considered, though data on long-term neonatal outcomes remain limited.

Close obstetric surveillance follows diagnosis: serial fetal growth assessments via ultrasound, antenatal testing (e.g., nonstress tests or biophysical profiles) beginning at 32–36 weeks, and individualized timing of delivery—often recommended between 39 and 40 weeks’ gestation in well-controlled cases, unless complications arise. Postpartum, women with GDM should undergo a 75-g oral glucose tolerance test at 6–12 weeks to assess for persistent dysglycemia; they face a significantly elevated lifetime risk of developing type 2 diabetes and warrant ongoing metabolic screening every 1–3 years.